Tags

Type your tag names separated by a space and hit enter

Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab.
Mult Scler. 2018 05; 24(6):811-813.MS

Abstract

BACKGROUND

Alemtuzumab is a humanized monoclonal antibody directed at CD52 approved as a disease-modifying therapy for relapsing forms of multiple sclerosis (MS).

OBJECTIVE

To describe a case of a life-threatening autoimmune anemia occurring after a first course of alemtuzumab for relapsing-remitting MS in a 28-year-old male.

METHODS

Case report.

RESULTS

A 28-year-old male developed a life-threatening autoimmune anemia occurring 11 months after first alemtuzumab course.

CONCLUSION

We report the third case of autoimmune hemolytic anemia following treatment with alemtuzumab in a young MS patient. Due to the severity of this adverse event, neurologists using this treatment should be alert.

Links

Publisher Full Text

Authors+Show Affiliations

Meunier B
Département de médecine interne, Hôpital de la Timone, APHM, Marseille France.
Rico A
Service de Neurologie, Pôle de Neurosciences Cliniques, Hôpital de la Timone, APHM, Marseille, France.
Seguier J
Département de médecine interne, Hôpital de la Timone, APHM, Marseille France.
Boutiere C
Service de Neurologie, Pôle de Neurosciences Cliniques, Hôpital de la Timone, APHM, Marseille, France.
Ebbo M
Département de médecine interne, Hôpital de la Timone, APHM, Marseille France.
Harle JR
Département de médecine interne, Hôpital de la Timone, APHM, Marseille France.
Schleinitz N
Département de médecine interne, Hôpital de la Timone, APHM, Marseille France.
Pelletier J
Service de Neurologie, Pôle de Neurosciences Cliniques, Hôpital de la Timone, APHM, Marseille, France.

MeSH

AdultAlemtuzumabAnemia, Hemolytic, AutoimmuneHumansImmunologic FactorsMaleMultiple Sclerosis, Relapsing-Remitting

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

29359614

Citation

Meunier, Benoit, et al. "Life-threatening Autoimmune Warm Hemolytic Anemia Following Treatment for Multiple Sclerosis With Alemtuzumab." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 24, no. 6, 2018, pp. 811-813.
Meunier B, Rico A, Seguier J, et al. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. Mult Scler. 2018;24(6):811-813.
Meunier, B., Rico, A., Seguier, J., Boutiere, C., Ebbo, M., Harle, J. R., Schleinitz, N., & Pelletier, J. (2018). Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. Multiple Sclerosis (Houndmills, Basingstoke, England), 24(6), 811-813. https://doi.org/10.1177/1352458517729766
Meunier B, et al. Life-threatening Autoimmune Warm Hemolytic Anemia Following Treatment for Multiple Sclerosis With Alemtuzumab. Mult Scler. 2018;24(6):811-813. PubMed PMID: 29359614.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. AU - Meunier,Benoit, AU - Rico,Audrey, AU - Seguier,Julie, AU - Boutiere,Clemence, AU - Ebbo,Mikael, AU - Harle,Jean Robert, AU - Schleinitz,Nicolas, AU - Pelletier,Jean, Y1 - 2018/01/23/ PY - 2018/1/24/pubmed PY - 2019/9/7/medline PY - 2018/1/24/entrez KW - Multiple sclerosis KW - alemtuzumab KW - hemolytic anemia SP - 811 EP - 813 JF - Multiple sclerosis (Houndmills, Basingstoke, England) JO - Mult Scler VL - 24 IS - 6 N2 - BACKGROUND: Alemtuzumab is a humanized monoclonal antibody directed at CD52 approved as a disease-modifying therapy for relapsing forms of multiple sclerosis (MS). OBJECTIVE: To describe a case of a life-threatening autoimmune anemia occurring after a first course of alemtuzumab for relapsing-remitting MS in a 28-year-old male. METHODS: Case report. RESULTS: A 28-year-old male developed a life-threatening autoimmune anemia occurring 11 months after first alemtuzumab course. CONCLUSION: We report the third case of autoimmune hemolytic anemia following treatment with alemtuzumab in a young MS patient. Due to the severity of this adverse event, neurologists using this treatment should be alert. SN - 1477-0970 UR - https://www.unboundmedicine.com/medline/citation/29359614/Life_threatening_autoimmune_warm_hemolytic_anemia_following_treatment_for_multiple_sclerosis_with_alemtuzumab_ L2 - https://journals.sagepub.com/doi/10.1177/1352458517729766?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -